Headlands Technologies LLC Invests $2.52 Million in BioNTech SE Sponsored ADR $BNTX

Headlands Technologies LLC acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 27,087 shares of the company’s stock, valued at approximately $2,520,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Larson Financial Group LLC raised its holdings in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. EFG International AG bought a new position in shares of BioNTech during the fourth quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after purchasing an additional 260 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the period. Finally, Vestcor Inc purchased a new position in shares of BioNTech in the 4th quarter valued at $153,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on BNTX shares. Morgan Stanley reduced their price objective on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. Berenberg Bank decreased their price target on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Finally, Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $127.81.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted COMIRNATY vaccine for the 2026–2027 season. Shipping is beginning immediately, potentially supporting near-term seasonal revenue and maintaining the product’s commercial presence. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: One investment analysis reiterated a Strong Buy rating, citing momentum in BioNTech’s late-stage oncology pipeline, strategic partnerships, and upcoming catalysts for gotistobart and pumitamig. Expected data at WCLC 2026 could help refocus investor attention on the company’s long-term growth prospects. BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
• Neutral Sentiment: Options activity was unusually bearish, with put purchases more than doubling typical volume. This signals heightened hedging or speculative downside expectations, but does not by itself establish a change in BioNTech’s fundamentals.
• Negative Sentiment: BioNTech decided to terminate a Phase 2 trial of autogene cevumeran in colorectal cancer. The setback weakens confidence in the company’s personalized mRNA cancer-vaccine strategy and removes a clinical catalyst, overshadowing the COMIRNATY approval. BioNTech to terminate mid-stage trial of mRNA cancer vaccine
• Negative Sentiment: The trial discontinuation triggered a sharp decline in the stock and raised concerns about the risks facing BioNTech’s oncology pipeline. Investors also remain cautious because COVID-19 vaccine demand and competition are pressuring revenue expectations, even as the XFG formulation expands COMIRNATY’s seasonal opportunity. BioNTech Terminates Phase 2 Trial Of Autogene Cevumeran In Colorectal Cancer

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $102.07 on Monday. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The business’s 50 day moving average price is $95.40 and its 200 day moving average price is $95.79. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The firm has a market cap of $25.81 billion, a P/E ratio of -13.04 and a beta of 1.27.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the prior year, the business posted ($1.60) earnings per share. The business’s quarterly revenue was down 59.5% compared to the same quarter last year. On average, sell-side analysts expect that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

BioNTech declared that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.